When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity

Michael Kremer and Christopher Snyder

Working Paper from Harvard University OpenScholar

Abstract: We argue that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer's ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. If consumers vary only in disease risk, revenue from treatments---sold after the disease is contracted, when disease risk is no longer a source of private information---always exceeds revenue from preventives. The revenue ratio can be arbitrarily high for sufficiently skewed distributions of disease risk. Under some circumstances, heterogeneity in harm from a disease, learned after a disease is contracted, can lead revenue from a treatment to exceed revenue from a preventative. Calibrations suggest that skewness in the U.S. distribution of HIV risk would lead firms to earn only half the revenue from a vaccine as from a drug. Empirical tests are consistent with the predictions of the model that vaccines are less likely to be developed for diseases with substantial disease-risk heterogeneity.

Date: 2013-01
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://scholar.harvard.edu/kremer///////////////// ... //////////node/70726

Related works:
Working Paper: When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity (2013)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:qsh:wpaper:70726

Access Statistics for this paper

More papers in Working Paper from Harvard University OpenScholar Contact information at EDIRC.
Bibliographic data for series maintained by Richard Brandon ( this e-mail address is bad, please contact ).